脑卒中与血小板活化因子及其受体拮抗剂

Stroke,platelet activating factor and receptor antagonists

脑卒中是一种急性脑血管疾病,具有发病率高、致残率和致死率高的特点。全球脑卒中防治形势严峻,抗血小板聚集治疗能够有效防治脑卒中。血小板活化因子(PAF)是介导血小板聚集的另一重要介质,在脑卒中病理过程中起着重要作用。近年来,PAF受体拮抗剂在脑卒中防治领域逐渐引起国际关注。该文对PAF受体拮抗剂的分类、作用机制及药物特征进行综述,以期对临床用药及新药研发提供有价值的指导和方向。

Stroke is an acute cerebrovascular disease with high morbidity, disability and mortality. The prevention and treatment conditions for stroke is severe all over the world. Antiplatelet aggregation is an effective treatment. Platelet activation factor （PAF） is another important medium in mediating platelet aggregation, which plays an important role in the pathogenesis of stroke. In recent years, PAF receptor antagonists have attracted international attention in the field of stroke prevention and treatment. In this review, we would summarize the classification, mechanism and drug characteristics of PAF receptor antagonists in order to provide the valuable guidance and direction for clinical medicine and research.